UK rejects cannabis bill already approved by Bermuda lawmakers

The United Kingdom instructed the governor of Bermuda to reject the island nation’s pending cannabis law on the basis that it breaches international obligations set out in United Nations drug-control treaties.

Top CBD companies experience market share drop as online sales soften

The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return of in-person shopping triggered a decline in e-commerce sales.

Market share by revenue for the top 20 CBD brands shrank 2 percentage points, to 16%, versus the first quarter of the year, according to Chicago-based cannabis analytics firm Brightfield Group.

Hawthorne buys Flowr’s cannabis research facility for CA$16 million 

Hawthorne Canada completed the purchase of The Flowr Corp.’s Kelowna research and development facility for 15.9 million Canadian dollars ($12.4 million), the companies announced Wednesday.

Canadian cannabis producer Flowr cuts 40% of staff, sells assets to save cash 

Canadian cannabis producer The Flowr Corp. eliminated 40% of its workforce and sold a large parcel of land in a bid to save cash.

EU pause on CBD won’t affect thousands of products on UK shelves – for now

British health regulators say that thousands of CBD products currently on store shelves in the United Kingdom aren’t in immediate danger of removal because European Union officials are delaying plans to authorize CBD-infused foods and dietary supplements.

European Union taps the brakes on CBD foods and supplements

European Union regulators are hitting the pause button on plans to allow CBD to be sold over the counter and added to foods and dietary supplements.

As more states legalize marijuana, CBD retailers face an identity crisis

Legal and lightly taxed, CBD operators have enormous business advantages compared to their colleagues growing and selling high-THC cannabis and its extracts.

But how will they fit in the overall cannabis industry when all THC levels – think recreational marijuana – are legal?

The future of cannabis retail amid complex regulations: Q&A with Your CBD Store executives

Jay Benge and Ryan Sinclair of Your CBD Store discuss how a large, multistate cannabis retailer captures the wellness-minded consumer amid complex regulations,

Can potential growth aid this cannabis stock? + strategic planning alternative

The Kanabo Group is banking on potential growth to correct its stock trend, and how to best use scenario planning in lieu of strategic planning.

Court tosses Canopy cannabis patent infringement lawsuit against GW Pharma

A Texas court has dismissed a lawsuit brought by Canadian cannabis producer Canopy Growth against GW Pharmaceuticals, although Canopy has the right to appeal the ruling.

Marijuana M&A sizzled in 2021 and is poised for a hot 2022

Marijuana merger and acquisition activity proceeded at a torrid pace in 2021 – and could accelerate in 2022 – thanks to lower interest costs and pressure on larger companies to expand their footprints and boost revenue.

German pharma firm Dermapharm buying Canopy’s cannabinoid subsidiary C3

German pharmaceutical manufacturer Dermapharm Holding SE has struck a deal to buy C3 Cannabinoid Compound Co. GmbH from Canadian cannabis producer Canopy Growth.